Press Releases
 
Cytomegalovirus Retinitis Market Trends, Size, Growth and Demand, 2023

United States, 8 December 2017 -- One of the major trends noticed in the cytomegalovirus retinitis market is usage of off-label drugs for the treatment of cytomegalovirus retinitis.

Innovation of products focusing on better efficacy, growing demographics and growing economies in the developing countries, such as China and India, are some of the opportunities for global cytomegalovirus retinitis market.

Cytomegalovirus retinitis is eye disease caused due to retina inflammation of eye. The causative agent of the disease is cytomegalovirus, a herpes virus that affects the photosensitive cells of retina. After affecting the retina, the disease spreads from one eye to another eye, which can lead to blindness, if left untreated. Photophobia, blurred vision, seeing floaters and blind spots are the symptoms of cytomegalovirus retinitis. Cytomegalovirus retinitis usually affects people with weak immune system, including HIV affected patients. Various forms of cytomegalovirus retinitis medication are solutions, capsules, tablets and implants.

To know more about Cytomegalovirus Retinitis Market: https://www.psmarketresearch.com/market-analysis/cytomegalovirus-retinitis-market

Cytomegalovirus retinitis is an emergency situation because if a black spot in the visual field appears once, the disease cannot be cured due to its permanent in nature. If posterior pole is involved, it leads to approximately one half of incident visual acuity loss. Ophthalmology is the branch of medical science that deals with the study and management of physiology, anatomy and the diseases related to the human eye. The vision loss and incidence of eye disorders are becoming a major public health issues which include various eye diseases such as glaucoma, age-related macular degeneration, cataract, diabetic macular edema, retinal detachment, ocular hypertension, bulging eyes, refractive errors and uveitis. Active cytomegalovirus retinitis is generally treated by uveitis or ocular immunology specialist. Fomivirsen was the first antisense drug approved by the U.S. Food and Drug Administration (FDA) as an intraocular injection for curing cytomegalovirus retinitis. As the virus creates a worse effect to vision, it is generally treated by a vitreoretinal surgeon with the help of antivirals, such as ganciclovir or foscarnet, which can be taken orally or directly into the eye.

Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/cytomegalovirus-retinitis-market/report-sample

Some of the major competitors of global cytomegalovirus retinitis market are, Shire Plc, F. Hoffmann-La Roche AG, Hospira Inc., Chimerix Inc., Gilead Sciences Inc., pSivida, Auritec Pharmaceuticals Inc., Sanofi S.A., and Isis Pharmaceuticals Inc.

# # #


Submitted by Jacob, P&S Market Research on Friday, 8 December 2017 at 6:18 AM
Category: Health Care & Medical
 
Related News

Novotech and CNS deal expands CRO services for Biopharma Clients across Asia-Pacific
Friday, 19 Oct 2018

Solve.Care is presenting its healthcare on blockchain solution at the biggest healthcare conference
Friday, 19 Oct 2018

Pompe Disease Market 2016 - 2024: End Users, Region, Growth Rate and Sales
Thursday, 18 Oct 2018

B-Type Natriuretic Peptide Testing Market - Size, Share, Growth, Trends, and Forecast 2013 - 2019
Thursday, 18 Oct 2018

Process Chromatography Market Dynamics, Forecast, Analysis and Supply Demand 2015 - 2023
Thursday, 18 Oct 2018

Related Events

Mayo Clinic Updates in Internal Medicine 2018
Thursday, 18 Oct 2018

34th World Congress of Internal Medicine (WCIM 2018)
Thursday, 18 Oct 2018

Food Allergy and Anaphylaxis Meeting (FAAM 2018)
Thursday, 18 Oct 2018

2nd WAidid Congress
Thursday, 18 Oct 2018

Abu Dhabi International Mental Health Conference, 2018
Friday, 19 Oct 2018

Latest News

Democrats RISE UP With a New Song from the Mark Williams
Friday, 19 Oct 2018

Amazing Surprised You-450M Runescape Gold Only for Free&Nic the Trader Oct. 22
Friday, 19 Oct 2018

RS 07 Gold with Up to $12,000 cash coupons on Rsorder for Portal Nexus Oct. 22
Friday, 19 Oct 2018

Novotech and CNS deal expands CRO services for Biopharma Clients across Asia-Pacific
Friday, 19 Oct 2018

Solve.Care is presenting its healthcare on blockchain solution at the biggest healthcare conference
Friday, 19 Oct 2018

 
Want to get your press releases, event listings, and job ads on Scoopasia? Register now for a FREE account or login if you already have one!
Scoopasia v1.0b. Copyright © 2018
Today is Friday, 19 October 2018

About Scoopasia | FAQ | Privacy Policy | Contact Us

Press Releases
Event Listings
Job Listings
Arts & Entertainment
Architecture & Construction
Automotive & Travel
Business
Consumer Technology
Economy
Education
Enterprise Technology
Food & Fashion
Government & Policy
Health Care & Medical
Legal/Law
News & Media
Religion
Science & Research
Sports & Fitness
Login / Register
Get Scoopasia through RSS Feeds & Email Notifications!


Journalist's Toolbox
Hello journalist, welcome to Scoopasia--a powerful online resource for media information in Asia. Scoopasia has press releases and media events for every beat and industry. All content on Scoopasia is 100% FREE. You don't even need to login!

  • Scoop Line
    (Instant Information Request)
    The easiest way to ask questions and request information from the PR community.


  • Advanced Search
    Drill down, dig deep, for media information the way you want it.

  • Journalist's Resources
    Resources and tools you can't do without.

  • PR Tools
    Scoopasia Blog Search
    Search the largest handpicked collection of Asia's most prominent and influential blogs.


    Resources
  • PR Bookmarks
  • Web 2.0 Bookmarks
  • Media Bookmarks

    More Coming Soon...

  • Upcoming Events
  • Palo Alto Networks: CYBERFORCE: AN ELITE GROUP OF PROFESSIONALS IN CYBERSECURITY
  • Mediterranean Resort and Hotel Real Estate Forum
  • Mayo Clinic Updates in Internal Medicine 2018
  • Palo Alto Networks: BEST PRACTICE ASSESSMENT: MAXIMIZING THE USE OF THE PALO ALTO NETWORKS PLATFORM
  • EyeforTravel North America

  • Latest Jobs
    Sorry, there are currently no entries posted here.